DK3519416T3 - Chroman, isochroman og dihydroisobenzofuranderivater som mglur2-negative allosteriske modulatorer, sammensætninger og anvendelse deraf - Google Patents

Chroman, isochroman og dihydroisobenzofuranderivater som mglur2-negative allosteriske modulatorer, sammensætninger og anvendelse deraf Download PDF

Info

Publication number
DK3519416T3
DK3519416T3 DK17781253.4T DK17781253T DK3519416T3 DK 3519416 T3 DK3519416 T3 DK 3519416T3 DK 17781253 T DK17781253 T DK 17781253T DK 3519416 T3 DK3519416 T3 DK 3519416T3
Authority
DK
Denmark
Prior art keywords
mglur2
isochroman
chroman
compositions
allosteric modulators
Prior art date
Application number
DK17781253.4T
Other languages
English (en)
Inventor
Iyassu K Sebhat
Ashok Arasappan
Scott B Hoyt
Robert R Wilkening
Duane Demong
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of DK3519416T3 publication Critical patent/DK3519416T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • A61K31/015Hydrocarbons carbocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/02Halogenated hydrocarbons
    • A61K31/025Halogenated hydrocarbons carbocyclic
    • A61K31/03Halogenated hydrocarbons carbocyclic aromatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22Bridged ring systems
    • C07D221/24Camphidines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17781253.4T 2016-09-27 2017-09-25 Chroman, isochroman og dihydroisobenzofuranderivater som mglur2-negative allosteriske modulatorer, sammensætninger og anvendelse deraf DK3519416T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662400150P 2016-09-27 2016-09-27
PCT/US2017/053155 WO2018063955A1 (en) 2016-09-27 2017-09-25 CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE

Publications (1)

Publication Number Publication Date
DK3519416T3 true DK3519416T3 (da) 2021-05-25

Family

ID=60043302

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17781253.4T DK3519416T3 (da) 2016-09-27 2017-09-25 Chroman, isochroman og dihydroisobenzofuranderivater som mglur2-negative allosteriske modulatorer, sammensætninger og anvendelse deraf

Country Status (39)

Country Link
US (4) US10335399B2 (da)
EP (1) EP3519416B1 (da)
JP (3) JP6681517B2 (da)
KR (1) KR102296043B1 (da)
CN (1) CN109983022B (da)
AR (1) AR109714A1 (da)
AU (2) AU2017334870C1 (da)
CA (1) CA3037537C (da)
CL (1) CL2019000778A1 (da)
CO (1) CO2019002673A2 (da)
CR (1) CR20190147A (da)
CY (1) CY1124346T1 (da)
DK (1) DK3519416T3 (da)
DO (1) DOP2019000076A (da)
EA (1) EA038627B1 (da)
EC (1) ECSP19020742A (da)
ES (1) ES2868973T3 (da)
GE (2) GEP20217279B (da)
HR (1) HRP20210793T1 (da)
HU (1) HUE054898T2 (da)
IL (1) IL265366B (da)
JO (1) JOP20190058B1 (da)
LT (1) LT3519416T (da)
MA (1) MA46342B1 (da)
MD (1) MD3519416T2 (da)
MX (1) MX2019003492A (da)
MY (1) MY196807A (da)
NI (1) NI201900025A (da)
PE (1) PE20190609A1 (da)
PH (1) PH12019500597A1 (da)
PL (1) PL3519416T3 (da)
PT (1) PT3519416T (da)
RS (1) RS61890B1 (da)
SI (1) SI3519416T1 (da)
TN (2) TN2020000161A1 (da)
TW (1) TWI764934B (da)
UA (1) UA123687C2 (da)
WO (1) WO2018063955A1 (da)
ZA (1) ZA201901701B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3519416T3 (pl) * 2016-09-27 2021-09-06 Merck Sharp & Dohme Corp. Pochodne chromanu, izochromanu i dihydroizobenzofuranu jako ujemne allosteryczne modulatory mglur2, ich kompozycje i zastosowanie
MA51620A (fr) 2018-01-19 2020-11-25 Cytokinetics Inc Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques
US11964967B2 (en) 2018-06-26 2024-04-23 Cytokinetics, Inc. Cardiac sarcomere inhibitors
BR112021017276A2 (pt) * 2019-03-01 2021-11-09 Kbp Biosciences Co Ltd Método para preparar composto tricíclico e intermediário do mesmo
KR20240015622A (ko) 2021-03-04 2024-02-05 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
WO2023278729A1 (en) * 2021-06-30 2023-01-05 The General Hospital Corporation Chromane imaging ligands

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552437A (en) 1994-10-27 1996-09-03 Merck Frosst Canada, Inc. Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis
US5576338A (en) 1995-02-15 1996-11-19 Merck Frosst Canada, Inc. Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのhcvポリメラーゼ阻害剤としての利用
WO2007038865A1 (en) 2005-10-05 2007-04-12 Merck Frosst Canada Ltd. Substituted quinolines as inhibitors of leukotriene biosynthesis
AR065093A1 (es) 2007-02-05 2009-05-13 Merck Frosst Canada Ltd Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos
BRPI0917394A2 (pt) 2008-08-18 2019-09-24 Univ Yale moduladores de mif
MY161325A (en) * 2009-05-12 2017-04-14 Janssen Pharmaceuticals Inc 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
WO2011075699A2 (en) 2009-12-18 2011-06-23 Sunovion Pharmaceuticals Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
US9278960B2 (en) * 2011-11-03 2016-03-08 Merck Sharp & Dohme Corp. Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
WO2016029454A1 (en) 2014-08-29 2016-03-03 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
US9382208B1 (en) 2015-01-26 2016-07-05 Vanderbilt University Negative allosteric modulators of metabotropic glutamate receptor 2
US10538491B2 (en) 2015-03-16 2020-01-21 Vanderbilt University 4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators
JP6471614B2 (ja) 2015-05-29 2019-02-20 株式会社リコー 通信端末、通信システム、通信制御方法、及びプログラム
JP2018154554A (ja) 2015-07-29 2018-10-04 大日本住友製薬株式会社 新規リンカー部位を持つ縮合ピラゾール誘導体およびその医薬用途
PL3519416T3 (pl) * 2016-09-27 2021-09-06 Merck Sharp & Dohme Corp. Pochodne chromanu, izochromanu i dihydroizobenzofuranu jako ujemne allosteryczne modulatory mglur2, ich kompozycje i zastosowanie

Also Published As

Publication number Publication date
NI201900025A (es) 2019-05-27
AR109714A1 (es) 2019-01-16
JOP20190058A1 (ar) 2019-03-24
DOP2019000076A (es) 2019-07-15
US20220218676A1 (en) 2022-07-14
MX2019003492A (es) 2019-09-19
MY196807A (en) 2023-05-03
ES2868973T3 (es) 2021-10-22
HRP20210793T1 (hr) 2021-09-03
CL2019000778A1 (es) 2019-05-31
CA3037537A1 (en) 2018-04-05
PT3519416T (pt) 2021-05-13
LT3519416T (lt) 2021-06-10
US20190247374A1 (en) 2019-08-15
CR20190147A (es) 2019-05-17
IL265366B (en) 2021-12-01
CN109983022A (zh) 2019-07-05
GEP20217266B (en) 2021-06-25
JP2020111596A (ja) 2020-07-27
HUE054898T2 (hu) 2021-10-28
JP6681517B2 (ja) 2020-04-15
PH12019500597A1 (en) 2019-07-24
CO2019002673A2 (es) 2019-03-29
US10335399B2 (en) 2019-07-02
GEP20217279B (en) 2021-08-10
EA038627B1 (ru) 2021-09-24
AU2017334870B2 (en) 2020-08-20
AU2020270468B2 (en) 2022-02-17
EP3519416B1 (en) 2021-03-31
CY1124346T1 (el) 2022-07-22
EP3519416A1 (en) 2019-08-07
AU2017334870C1 (en) 2020-12-17
US20210015800A1 (en) 2021-01-21
CN109983022B (zh) 2022-06-07
TN2020000161A1 (en) 2022-04-04
ZA201901701B (en) 2023-03-29
EA201990818A1 (ru) 2019-08-30
US10806724B2 (en) 2020-10-20
MD3519416T2 (ro) 2021-09-30
ECSP19020742A (es) 2019-04-30
KR102296043B1 (ko) 2021-08-30
TWI764934B (zh) 2022-05-21
TW201815794A (zh) 2018-05-01
PE20190609A1 (es) 2019-04-23
MA46342B1 (fr) 2021-05-31
AU2020270468A1 (en) 2020-12-10
CA3037537C (en) 2021-06-15
MA46342A (fr) 2019-08-07
SI3519416T1 (sl) 2021-08-31
JP2020011989A (ja) 2020-01-23
RS61890B1 (sr) 2021-06-30
JOP20190058B1 (ar) 2023-09-17
AU2017334870A1 (en) 2019-03-28
UA123687C2 (uk) 2021-05-12
JP2019529468A (ja) 2019-10-17
WO2018063955A1 (en) 2018-04-05
PL3519416T3 (pl) 2021-09-06
JP6992109B2 (ja) 2022-02-15
BR112019005869A2 (pt) 2019-06-11
IL265366A (en) 2019-05-30
KR20190056418A (ko) 2019-05-24
TN2020000160A1 (en) 2022-04-04
US20180085358A1 (en) 2018-03-29
BR112019005869A8 (pt) 2023-05-02
JP6945605B2 (ja) 2021-10-06

Similar Documents

Publication Publication Date Title
DK3519416T3 (da) Chroman, isochroman og dihydroisobenzofuranderivater som mglur2-negative allosteriske modulatorer, sammensætninger og anvendelse deraf
DK3394033T3 (da) Heterocykliske forbindelser som immunmodulatorer
DK3407888T3 (da) Pyridopyrroloquinoxalinforbindelser, deres sammensætninger og anvendelser
DK3341367T3 (da) Bicyklisk-fusionerede heteroaryl- eller arylforbindelser som irak4-modulatorer
DK3347472T3 (da) Sammensætninger som indeholder cyp76ad1- clade polypeptider og anvendelse heraf.
EP3229789A4 (en) Microencapsulated cannabinoid compositions
DK3328849T3 (da) 1,1,1-trifluor-3-hydroxypropan-2-yl-carbamat-derivater og 1,1,1-trifluor-4-hydroxybutan-2-yl-carbamat-derivater som magl-inhibitorer
DK3258942T3 (da) Kosmetiske og topiske sammensætninger omfattende cannabigerol og cannabidiol
IL243671B (en) Sulfonamides for modulating sodium channels, preparations containing them and their uses
EP3283080A4 (en) Compositions for modulating c9orf72 expression
DK3363790T3 (da) 1,2,4-oxadiazolderivater som immunmodulatorer
DK3313832T3 (da) 3-tetrazolyl-benzen-1,2-disulfonamidderivater som metallo-beta- lactamase-hæmmere
DK3294713T3 (da) Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer
DK3071709T3 (da) Mikrobiotasammensætning som en markør for modtagelighed over for kemoterapi og anvendelse af mikrobielle modulatorer (præ-, pro- eller synbiotika) til forbedring af virkningsgraden af en cancerbehandling
DK3377483T3 (da) N-substituerede indolderivater som pge2-receptormodulatorer
DK3331863T3 (da) Hidtil ukendte forbindelser som ror-gamma-modulatorer
DK3712150T3 (da) Makrocyklisk forbindelse, der tjener som wee1-hæmmer, og anvendelser deraf
DK3625222T3 (da) Phenylderivater som pge2-receptormodulatorer
DK2861573T3 (da) Oxathiazin-derivater som antibakterielle og anticancer-stoffer
DK3126361T3 (da) Chromen og 1,1a,2,7b-tetrahydrocyclopropa[c]chromen- pyridopyrazindioner som gamma-sekretase-modulatorer
DK3464260T3 (da) Forbindelser, der indeholder ureamotiver, og derivater deraf som antibakterielle lægemidler
EP3185865A4 (en) TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
DK3292105T3 (da) Pyrazolderivater, der er anvendelige som inhibitorer af 5-lipoxygenase-aktiverende protein (flap)
DK3003493T3 (da) Enzymatisk system, som indeholder kosmetiske sammensætninger
DK3468964T3 (da) Modulatorer af SOCE, sammensætninger og anvendelser deraf